Clinical Trials Sponsored by Macopharma

Total 33 results

ApoPharma

Completed

Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers

Healthy

Canada
ApoPharma

Completed

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

United States, Canada
ApoPharma

Completed

Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects

Asymptomatic HIV Infection

South Africa
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
ApoPharma

Completed

A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia

Friedreich's Ataxia

Belgium, France, Italy, Spain
ApoPharma

Completed

A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

Friedreich's Ataxia

Canada, Australia, Belgium, France, Italy, Spain
ApoPharma

Completed

Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients

Iron Overload

Egypt, Indonesia, Malaysia
Micropharma Limited

Completed

Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile

Hypercholesterolemia
Micropharma Limited

Completed

Efficacy of Cardioviva™ Probiotic Yogurt Formulation

Hypercholesterolemia
Micropharma Limited

Completed

Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation

Hypercholesterolemia

Czech Republic
ApoPharma

Completed

Efficacy Study in Removing Excess Iron From the Heart

Hemosiderosis | Thalassemia Major

Greece, Italy
ApoPharma

Completed

Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

Sickle Cell Disease

Canada
ApoPharma

Completed

A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers

Healthy Volunteers

Canada
ApoPharma

Completed

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

Prolonged QTc Interval

United States
ApoPharma

Completed

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

Hepatic Impairment

United States
ApoPharma

Completed

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

Renal Impairment

Canada
ApoPharma

Completed

Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects

HIV Infection

South Africa
ApoPharma

Completed

Active Drug Surveillance Program of Ferriprox Use

Transfusional Iron Overload

Egypt, Cyprus, Oman, Saudi Arabia, Turkey
ApoPharma

Terminated

Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

Diabetic Foot Ulcer

United States
Micropharma Limited

Completed

Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule

Hypercholesterolemia

Canada
ApoPharma

Completed

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration (TIRCON-EXT)

Pantothenate Kinase-Associated Neurodegeneration

United States, Germany, Italy, United Kingdom
University Hospital, Lille
ApoPharma

Completed

Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients (SAFEFAIRALS)

ALS (Amyotrophic Lateral Sclerosis) | Iron Overload

France
Jules Bordet Institute
Macopharma; Belgian Hematological Society

Recruiting

Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Refractory Chronic Graft Versus Host Disease (cGVHD)

Belgium
ApoPharma

Terminated

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Iron Overload | Sickle Cell Disease | Other Anemias

United States, United Kingdom, Egypt, Canada, Saudi Arabia
ApoPharma

Terminated

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (FIRST)

Iron Overload | Sickle Cell Disease | Other Anemias

United States, Turkey, United Kingdom, Egypt, Saudi Arabia, Brazil, Canada, Tunisia
University of Manitoba
Micropharma Limited

Completed

Efficacy of Two Yogurt Formulations in Healthy Humans (MPH)

Healthy
Children's Hospital of Philadelphia
ApoPharma

Approved for marketing

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

Iron Overload

United States
ApoPharma

Completed

Study of Parkinson's Early Stage With Deferiprone (SKY)

Parkinson's Disease

United Kingdom, France, Germany, Canada
ApoPharma

Completed

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload (TWICE)

Iron Overload Due to Repeated Red Blood Cell Transfusions

United States, Canada, Greece, Italy
ApoPharma
Algorithme Pharma Inc

Completed

Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

Healthy

Canada
MDCPharma Produtos Farmaceuticos LTDA

Unknown

Study to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex

Anorexia | Lack of Appetite

Brazil
University Hospital, Lille
European Commission; ApoPharma

Completed

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)

Parkinson Disease

Netherlands, Spain, France, Portugal, Czechia, United Kingdom, Austria, Germany
ApoPharma
Food and Drug Administration (FDA)

Completed

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

Pantothenate Kinase-Associated Neurodegeneration

United States, Germany, Italy, United Kingdom

3

Subscribe